Clinical Trials
49 trialsEvaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
University of Washington
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
TAPUR
American Society of Clinical Oncology
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
ABBY
Abramson Cancer Center at Penn Medicine
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
I-SPY
QuantumLeap Healthcare Collaborative
ALEPRO
Universitaire Ziekenhuizen KU Leuven
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
UPLIFT
University of California, San Francisco
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
EndoMAP
Alliance Foundation Trials, LLC.
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
MiRaDoR
MedSIR
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The Methodist Hospital Research Institute
GERTRUDE
Dartmouth-Hitchcock Medical Center
BRE-09
University of Illinois at Chicago
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
AURA
Japanese Foundation for Cancer Research
ROYAL
Azienda Ospedaliero-Universitaria di Modena
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Dana-Farber Cancer Institute
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
MINERVA
University of Ulm
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NICHOL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Neo-AGILE
Fondazione Oncotech
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
FINPROVE
Helsinki University Central Hospital
Rainbow
Fudan University
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
DRUP
The Netherlands Cancer Institute
ORACLE-RIPA
National Taiwan University Hospital